Literature DB >> 23609167

Risk profile of hepatocellular carcinoma reveals dichotomy among US veterans.

Raffi Karagozian1, Errol Baker, Antoun Houranieh, Daniel Leavitt, György Baffy.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is traditionally associated with chronic liver injury resulting from hepatitis B virus (HBV) and hepatitis C virus (HCV) infection or excessive consumption of alcohol. In addition, recent evidence links HCC to diabetes. AIMS: Since these risk factors are prevalent among US veterans, we analyzedcontribution of various etiologies toHCC incidence in this population.
METHODS: Clinicopathological correlates of 150 male US veterans diagnosed with HCC between 2001 and 2010 were analyzed and compared to frequency-matched (2:1) non-cancer controls in a single center.
RESULTS: HCC was associated with cirrhosis (odds ratio [OR], 250.84; 95 % confidence interval [CI], 86.92-723.88; p < 0.0001), chronic hepatitis B (OR, 34.30 95 % CI, 1.97-598.47; p = 0.015), chronic hepatitis C (OR, 6.84; 95 % CI, 3.89-12.04; p < 0.0001), alcohol use (OR, 6.76; 95 % CI, 4.35-10.52; p < 0.0001), and smoking (OR, 1.83; 95 % CI, 1.23-2.89; p = 0.009), but surprisingly not with diabetes. Only in a subgroup of HCC patients with no "traditional" risk factors did diabetes become a strong independent predictor of HCC when compared to HCC patients with at least one such risk factor (OR, 10.69; 95 % CI, 1.88-60.63, p = 0.007). This subgroup was further distinguished by older age, increased prevalence of hypertension, nonsmoking, and a trend to develop noncirrhotic HCC.
CONCLUSIONS: While HCC in US veterans is overwhelmingly linked to cirrhosis due to "traditional" risk factors, it also occurs with a separate clinical profile characterized by diabetes and no evidence of cirrhosis, suggesting distinct mechanisms of hepatocarcinogenesis and needs for surveillance.

Entities:  

Mesh:

Year:  2013        PMID: 23609167     DOI: 10.1007/s12029-013-9499-1

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  30 in total

1.  Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.

Authors:  Shih-Wei Lai; Pei-Chun Chen; Kuan-Fu Liao; Chih-Hsin Muo; Cheng-Chieh Lin; Fung-Chang Sung
Journal:  Am J Gastroenterol       Date:  2011-11-15       Impact factor: 10.864

2.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

3.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

Review 4.  Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Ping Wang; Donghong Kang; Wei Cao; Yan Wang; Zhiwen Liu
Journal:  Diabetes Metab Res Rev       Date:  2012-02       Impact factor: 4.876

Review 5.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

6.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

7.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

8.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 9.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  4 in total

1.  Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.

Authors:  Petr Pancoska; Brian I Carr; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Semin Oncol       Date:  2014-04-24       Impact factor: 4.929

2.  Procyanidin B2 Attenuates Nicotine-Induced Hepatocyte Pyroptosis through a PPARγ-Dependent Mechanism.

Authors:  Jia Liu; Qinyu Yao; Xinya Xie; Qi Cui; Tingting Jiang; Ziwei Zhao; Xiong Du; Baochang Lai; Lei Xiao; Nanping Wang
Journal:  Nutrients       Date:  2022-04-22       Impact factor: 6.706

3.  Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population.

Authors:  Padmini Krishnamurthy; Nyla Hazratjee; Dan Opris; Sangeeta Agrawal; Ronald Markert
Journal:  J Gastrointest Oncol       Date:  2016-06

Review 4.  Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives.

Authors:  Diego García-Compeán; Emanuela Orsi; Ramesh Kumar; Felix Gundling; Tsutomu Nishida; Jesús Zacarías Villarreal-Pérez; Ángel N Del Cueto-Aguilera; José A González-González; Giuseppe Pugliese
Journal:  World J Gastroenterol       Date:  2022-02-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.